前研究表明，Spitz肿瘤主要发生在年轻患者身上，因此病理学家们不太愿意在老年人中诊断良性的Spitz肿瘤。随着基因组测序技术的发展，有必要重新评估现代分子时代Spitz肿瘤的流行病学。我们的目标是通过整合下一代测序（NGS）重新评估Spitz肿瘤的流行病学。我们研究了54,814例非Spitz肿瘤和1260例Spitz肿瘤，其中包括286例进行了NGS检测的Spitz肿瘤，并收集了各种流行病学数据。在我们的总体病例群中，Spitz肿瘤病例的比例在前四个年龄段中相对稳定，但在第五个年龄段急剧下降。在评估了一组基因组验证的Spitz肿瘤病例后，下降幅度显著降低，最多有20%的Spitz肿瘤病例发生在50岁以上的患者中。限制包括可用的基因组验证的Spitz肿瘤病例数量和可能存在的通过基因组检测的病例选择偏差。基因组验证可能使得对50岁以上患者的Spitz肿瘤病例更加自信地诊断，并避免黑色素瘤过度诊断。版权所有 © 2023，Elsevier Inc.发表。

Previous studies suggests that Spitz neoplasms occur primarily in younger patients, leading pathologists to shy away from diagnosing a benign Spitz neoplasm in the elderly. With the advent of genomic sequencing, there is a need for reappraisal of the epidemiology of Spitz neoplasms in the modern molecular era.We aim to reassess the epidemiology of Spitz neoplasms incorporating NGS.We looked at 54,814 non-Spitz neoplasms and 1260 Spitz neoplasms including 286 Spitz neoplasms with NGS testing and collected various epidemiologic data.In our general pool of cases, the proportion of Spitz neoplasm cases occurring is relatively the same in each of the first four decades of life with a precipitous drop in the 5th decade. In assessing a group of genomically verified cases of Spitz neoplasms, the drop was much less significant and up to 20% of all Spitz neoplasm cases occurred in patients over 50 years of age.Limitations included the number of genetically verified Spitz neoplasm cases available and a possible bias as to which cases undergo genomic testing.Genomic verification may allow more confident diagnosis of Spitz neoplasms in patients over 50 years of age and avoid melanoma overdiagnosis.Copyright © 2023. Published by Elsevier Inc.